Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer
Status:
Completed
Trial end date:
2003-10-01
Target enrollment:
Participant gender:
Summary
Multi-center, open-label, non-randomized Phase II study to evaluate the efficacy and safety
of OSI-7904L in gastric and GEJ cancers. Those patients who do not derive clinical benefit
after two cycles may be switched to a commonly used combination regimen.